Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 21, 2025Angewandte Chemie International Edition

HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking

View Full Paper
Ask AI
Bookmark
Share

Authors

SHShipeng HeWHWenjing HuangYZYaojin Zhu

Discussion

Loading...

Member takes

Overview

Novel HerTACs enhance targeted protein degradation in HER2-positive tumors, suggesting new avenues for precision oncology.

Key Points

  • HerTACs enable selective degradation of proteins in tumors, improving targeted treatment options.
  • The engineered HerTAC L2,5P demonstrates a DC50 of 156 nM against programmed death ligand 1 in HER2-positive cells.
  • Development involved peptide engineering and modeling for improved stability and efficacy in cancer models.
  • This strategy highlights the potential to expand treatment for additional immune targets, enhancing therapeutic options.

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/68af6bff7567bf4f94fe97d6https://doi.org/10.1002/anie.202511467
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking2025
  2. 2An Engineered Nanovesicles-Based Lysosome-Targeting Protein Degradation Platform (NV-TACs) for Cancer Immunotherapy2026
  3. 3Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions2025
  4. 4A Tumor-Specific Membrane Protein Degradation Platform via Covalent Reaction-Induced Aggregation2025
  5. 5Small-Molecule Ligands Targeting Lysosome-Shuttling Receptors and the Emerging Landscape of Lysosome-Targeting Chimeras2025